TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18823458
Drug: Gelatin-containing solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin-containing solution
Study: 12623505
Drug: Cisplatin-methotrexate chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-methotrexate chemotherapy (3 courses)
Study: 10349036
Drug: D,L-fenfluramine (FEN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-fenfluramine (FEN) 60 mg oral dose
Study: 1958601
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine with 5 micrograms/ml epinephrine
Study: 1958601
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine without epinephrine
Study: 7128675
Drug: PB-sodium 130
Normalized name: ceftizoxime
DrugBank: Ceftizoxime (DB01332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PB-sodium 130 mg i.v. (IV)
Study: 7128675
Drug: PB sodium
Normalized name: ceftizoxime
DrugBank: Ceftizoxime (DB01332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PB sodium 10 mg i.m. (IM)
Study: 7128675
Drug: PB acid
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB acid 100 mg orally (PO)
Study: 24575793
Drug: Sequential erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential erlotinib (150 mg/day on day 15 through day 28) and gemcitabine (1250 mg/m2 Day 1, 8 q28 days)
Study: 24575793
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (1000 mg/m2 Days 1, 8, 15 q28 days)
Study: 24575793
Drug: Sequential erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential erlotinib and gemcitabine (EG-arm)
Study: 24575793
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (G-arm)
Study: 17898508
Drug: Apple polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple polyphenols (600 mg/day for 12 weeks)
Study: 17898508
Drug: Hop bract
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hop bract polyphenol-containing capsules (600 mg/day for 12 weeks)
Study: 9602763
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg, 3 times per day for 8 days
Study: 9602763
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg, 3 times per day for 4 days
Study: 3344690
Drug: Daily self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-monitoring and adherence instructions
Study: 3344690
Drug: Weekly self-monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly self-monitoring only
Study: 31899001
Drug: HDA-L (high-disease-activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDA-L (high-disease-activity lesion)
Study: 14521170
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen with pre‐breakfast injections
Study: 14521170
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen with pre‐dinner injections
Study: 14521170
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen with bedtime injections
Study: 8554206
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with sulfonylurea
Study: 8554206
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with insulin
Study: 8554206
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diet alone)
Study: 16715913
Drug: Methylergometrine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylergometrine 0.2 mg bolus (MEM group; n = 34)
Study: 15477411
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/d during the open-label period
Study: 15477411
Drug: Drug-washout period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-washout period (no statin therapy)
Study: 11156874
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Hirudin and Unfractionated heparin)
Study: 9158354
Drug: Dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.3 ng/ml)
Study: 9158354
Drug: Dexmedetomidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6 ng/ml)
Study: 7967730
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside (3 g/m2 every 12 h for 6 days) with etoposide (100 mg/m2 days 7-9)
Study: 7967730
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside (3 g/m2 every 12 h for 6 days) alone
Study: 7967730
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (high-dose cytosine arabinoside with etoposide)
Study: 3310634
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g per day
Study: 3310634
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg per day
Study: 23656351
Drug: High-dose L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L-arginine (6 g/day for at least 24 months)
Study: 8932759
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 mu g inserted vaginally 12 hours before induced abortion (Group B)
Study: 8932759
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 mu g inserted vaginally 12 hours before induced abortion (Group A)
Study: 8932759
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 mu g orally 12 hours before induced abortion (Group C)
Study: 1448663
Drug: CCNU 130
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCNU 130 mg/m2, q.6 weeks
Study: 1448663
Drug: VM‐26 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM‐26 100 mg/m2 on day 1, plus CCNU 130 mg/m2 on day 2, q.6 weeks
Study: 1448663
Drug: Mizonidazole 12
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mizonidazole 12 mg/m2 total dose in 9 fractions
Study: 1448663
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2 on days 1,8, 15 and 21 of radiation therapy
Study: 1448663
Drug: Procarbazine, AZQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procarbazine, AZQ or DDMP used as single agents
Study: 30523750
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/d) for 14 weeks (Group A)
Study: 30523750
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/d) plus letrozole for 14 weeks (Groups B, C, D)
Study: 29768340
Drug: Mandibular single-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular single-implant overdentures
Study: 27634790
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (3 mg eszopiclone and 40% oxygen)
Study: 24603733
Drug: Proprioceptive neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive neuromuscular facilitation (PNF) self-administered using an elastic tube
Study: 15772683
Drug: Trimix (Tx)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimix (Tx) with varying doses of phentolamine (1 mg) and papaverine (5, 10, or 20 mg)
Study: 15772683
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PgE1) at doses of 2.5, 5, or 10 microg
Study: 10741192
Drug: Sufentanil 10
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 10 micrograms + Bupivacaine 2.5 mg
Study: 10741192
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 micrograms + Bupivacaine 2.5 mg
Study: 10741192
Drug: Plain Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain Bupivacaine 2.5 mg
Study: 10741192
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 mL saline) + Bupivacaine 2.5 mg
Study: 2257859
Drug: Controlled-release theophylline
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release theophylline 650 mg once daily in the evening
Study: 2257859
Drug: Controlled-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release terbutaline 7.5 mg b.d.
Study: 396305
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral hygiene control group
Study: 27604086
Drug: Lovaza (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza (1 capsule providing 465mg EPA and 375mg DHA)
Study: 25781221
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk consumed almost daily
Study: 23791061
Drug: Cold autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold autologous blood cardioplegic solution
Study: 23791061
Drug: Cold non-autologous
Normalized name: Autologous Non-Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (DB15867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold non-autologous blood cardioplegic solution
Study: 19879118
Drug: Pantoprazole 20mg
Normalized name: pantoprazole 20 MG
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole 20mg bd plus amoxicillin 1g bd plus clarithromycin 500mg bd for 10 days (Group D)
Study: 16780616
Drug: Acetylcysteine 1200
Normalized name: acetylcysteine 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 1200 mg the day before and 600 mg at the operative day
Study: 11153971
Drug: Five-sessions cognitive
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-sessions cognitive therapy (C5)
Study: 8186063
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg at 16.00 h)
Study: 8186063
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) (100 mg at 16.00 h)
Study: 2687687
Drug: Rimantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine (200 mg per day for 10 days)
Study: 8172091
Drug: 54 g
Normalized name: FLEX-ALL 454 GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 g psyllium-enriched cereal/d containing 7.3 g psyllium
Study: 8172091
Drug: 7.6 g
Normalized name: IODINE 7.6 g in 1 L TOPICAL CONCENTRATE [ICON 5000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.6 g of psyllium taken between meals
Study: 215338
Drug: Colestipol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (30 g/day) and diet
Study: 30910061
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide and diphenhydramine (control)
Study: 28745354
Drug: Isoflavone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone therapy (80 mg day-1)
Study: 15354150
Drug: Calcium-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-rich diet supplying at least 1,500 mg of calcium per day
Study: 11965512
Drug: Abacor (isolated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacor (isolated soy protein with high levels of isoflavones and cotyledon soy fibres), given as two daily liquid supplements for 6 weeks
Study: 11965512
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given as two daily liquid supplements for 6 weeks
Study: 10681768
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 4000U SOD immediately after radiotherapy
Study: 7716842
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg subcutaneously every 4 weeks and flutamide 250 mg orally three times daily 2 months before and during radiation therapy (Arm I)
Study: 7716842
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (Arm II)
Study: 28011612
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of oral vancomycin followed by a single 500-mL fecal transplantation (FT) by enema
Study: 28011612
Drug: 6-week taper
Normalized name: CAPER BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week taper of oral vancomycin
Study: 3055930
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of beta-carotene daily
Study: 25223504
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort with metformin
Study: 23953078
Drug: Newer therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer therapies and devices combined with comprehensive care plans involving adequate patient education
Study: 21131672
Drug: Horticultural therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy-based programming (HT-based); implemented twice weekly for 6 weeks at 4 treatment sites.
Study: 18055486
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (LD) and 10 mg maintenance dose (MD)
Study: 18055486
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD) and 75 mg maintenance dose (MD)
Study: 16005674
Drug: Climène (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climène (estradiol valerate 2 mg, from D1 to D21/cyproterone acetate 1 mg, from D12 to D21, followed by 7 days off)
Study: 16005674
Drug: Climodiène (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climodiène (estradiol valerate 2 mg/dienogest 2 mg)
Study: 8588386
Drug: Nasal nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nasal nocturnal oxygen therapy
Study: 2006994
Drug: Felodipine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine, 10 mg once daily (extended release)
Study: 31493287
Drug: Betrixaban 80
Normalized name: betrixaban 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban 80 mg qd for 35-42 days
Study: 29665762
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg vitamin B6 (pyridoxine hydrochloride) before bed for five consecutive days
Study: 29665762
Drug: B complex
Normalized name: B Complex
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B complex preparation containing a range of B vitamins
Study: 26755225
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium ascorbate (SA) gel, delayed bonding (1-week)
Study: 23279702
Drug: 1540-nm nonablative
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540-nm nonablative fractional laser therapy (NAFL), four treatments at monthly intervals
Study: 23279702
Drug: 1540-nm nonablative
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540-nm nonablative fractional laser therapy (NAFL)
Study: 10823761
Drug: Subcutaneous interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interleukin‐2 (IL‐2) at doses of 1.5 MIU, 4.5 MIU, and 7.5 MIU per dose, delivered by twice‐daily injection for 5 consecutive days every 8 weeks
Study: 10823761
Drug: Subcutaneous interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interleukin‐2 (IL‐2) at 4.5 MIU
Study: 10823761
Drug: Subcutaneous interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interleukin‐2 (IL‐2) at 7.5 MIU
Study: 10823761
Drug: Subcutaneous interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interleukin‐2 (IL‐2) at 1.5 MIU
Study: 27270858
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam) for 12 weeks
Study: 22578793
Drug: Temozolomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (100 mg/m², days 1-7 of 1 week on, 1 week off cycles)
Study: 20618554
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% gel
Study: 15774531
Drug: Insulin-mediated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-mediated glucose clearance in arm (1 pmol min-1 kg-1)
Study: 15774531
Drug: Insulin-mediated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-mediated glucose clearance in leg (1 pmol min-1 kg-1)
Study: 11938697
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (600 mg) of albendazole with fatty food
Study: 11938697
Drug: Mebendazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (100 mg, twice a day, fasting state)
Study: 8708885
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid (IVL) administration on day 5
Study: 8708885
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid (IVL) administration on day 14
Study: 1824799
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of sodium clodronate given intravenously as a 3‐hour infusion for 20 days
Study: 1824799
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of sodium clodronate given intravenously as a 3‐hour infusion for 10 days
Study: 1824799
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of sodium clodronate given intravenously as a 3‐hour infusion for both groups
Study: 6653647
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg t.i.d.
Study: 6653647
Drug: Combined verapamil
Normalized name: verapamil, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined verapamil (80 mg t.i.d.) and quinidine (160 mg t.i.d.)
Study: 26829478
Drug: Standardized pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardized pre-operative telephone checklist administered between 7 and 3 days before surgery.
Study: 25146896
Drug: Fomentation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fomentation without any medicine (Control Group)
Study: 17984186
Drug: Alemtuzumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (30 mg three times per week, for up to 12 weeks)
Study: 17984186
Drug: Chlorambucil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (40 mg/m2 every 28 days, for up to 12 months)
Study: 15918057
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of valsartan (80 mg/day) and perindopril (4 mg/day)
Study: 1341206
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 75 mg daily for 6 months
Study: 1341206
Drug: Almitrine combined
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine combined with oxygen (8-10 L/min)
Study: 6605310
Drug: Tinoridine 200
Normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinoridine 200 mg
Study: 6605310
Drug: Tinoridine 400
Normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinoridine 400 mg
Study: 6605310
Drug: Tinoridine 800
Normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinoridine 800 mg
Study: 6605310
Drug: Tinoridine 200
Normalized name: Tinoridine
DrugBank: Tinoridine (DB13001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinoridine 200 mg (patients with renal disease)
Study: 29716563
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (2 × 18.5 mg PACs per day)
Study: 29716563
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (37 mg PACs per day)
Study: 29716563
Drug: Control dose
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control dose (2 × 1 mg PACs per day)
Study: 29716563
Drug: Control dose
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control dose (2 mg PACs per day)
Study: 26821189
Drug: PG201 (600mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG201 (600mg, 300mg twice daily)
Study: 26821189
Drug: SKI306X (600mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI306X (600mg, 200mg thrice daily)
Study: 23518215
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (MP) at 32 mg/day for seven days
Study: 23518215
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (MP) at 1 mg/kg/day for four days and 0.5 mg/kg/day for three days
Study: 23518215
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (MP)
Study: 23518215
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (MP)